TMR의 세계 인유두종바이러스 백신 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 이 보고서는 2017년부터 2031년까지의 기간 동안 시장을 분석하여 2023년을 기준 연도, 2031년을 예측 연도로 간주하여 세계 인유두종바이러스 백신의 수익을 제공합니다. 이 보고서는 2023년부터 2031년까지 세계 인유두종바이러스 백신 시장의 복합 연간 성장률(CAGR %)도 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 애널리스트가 인터뷰하는 방식으로 대부분의 조사 활동이 이루어졌습니다. 2차 조사에는 인유두종바이러스 백신 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.
이 보고서는 세계 인유두종바이러스 백신 시장의 경쟁 구도를 자세히 조사하고 있습니다. 세계 인유두종바이러스 백신 시장에서 활동하는 주요 기업들이 확인되었으며, 이들 각각은 다양한 속성 측면에서 프로파일링되었습니다. 회사 프로필, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 인유두종바이러스 백신 시장의 기업 속성입니다.
목차
제1장 서문
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계 시장 분석과 예측, 2017-2031년
제5장 중요한 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 인수합병
COVID-19 감염증 팬데믹이 업계에 미치는 영향
제6장 세계 시장 분석과 예측 : 가수별
소개와 정의
주요 조사 결과/발전
시장 금액 예측 : 가수별, 2017-2031년
2가
4가와 9가
시장 매력도 분석 : 가수별
제7장 세계 시장 분석과 예측 : 적응증별
소개와 정의
주요 조사 결과/발전
시장 금액 예측 : 적응증별, 2017-2031년
자궁경부암
항문암
질암
음경암
외음부암
중인두암
성기사마귀
기타
시장 매력도 분석 : 적응증별
제8장 세계 시장 분석과 예측 : 유통 채널별
소개와 정의
주요 조사 결과/발전
시장 금액 예측 : 유통 채널별, 2017-2031년
의사
도매업체
의사 판매대리점
정부기관
민관 얼라이언스
시장 매력도 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2017-2031년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력도 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 예측
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 상황
시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
Merck &Co., Inc.
GlaxoSmithKline plc
Sanofi
AstraZeneca
Serum Institute of India Pvt. Ltd.
Xiame Innovax Biotech Co., Ltd.
General Incorporated Foundation
The Chemo-Sero-Therapeutic Research Institute(Kaketsuken)
Bharat Biotechare
KSM
영문 목차
영문목차
Human Papillomavirus Vaccine Market - Scope of Report
TMR's report on the global human papillomavirus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global human papillomavirus vaccine market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global human papillomavirus vaccine market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the human papillomavirus vaccine market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global human papillomavirus vaccine market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global human papillomavirus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus vaccine market.
The report delves into the competitive landscape of the global human papillomavirus vaccine market. Key players operating in the global human papillomavirus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global human papillomavirus vaccine market profiled in this report.
Key Questions Answered in Global human papillomavirus vaccine Market Report:
What is the sales/revenue generated by human papillomavirus vaccine across all regions during the forecast period?
What are the opportunities in the global human papillomavirus vaccine market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Human Papillomavirus Vaccine Market - Research Objectives and Research Approach
The comprehensive report on the global human papillomavirus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global human papillomavirus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus vaccine market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Papillomavirus Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Valence, 2017-2031
6.3.1. Bivalent
6.3.2. Quadrivalent and Nonavalent
6.4. Market Attractiveness Analysis, by Valence
7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Cervical Cancer
7.3.2. Anal Cancer
7.3.3. Vaginal Cancer
7.3.4. Penile Cancer
7.3.5. Vulvar Cancer
7.3.6. Oropharyngeal Cancer
7.3.7. Genital Warts
7.3.8. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Physicians
8.3.2. Wholesalers
8.3.3. Physician Distributors
8.3.4. Government Entities
8.3.5. Public and Private Alliances
8.4. Market Attractiveness Analysis, by Indication
9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Human Papillomavirus Vaccine Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Valence, 2017-2031
10.3.1. Bivalent
10.3.2. Quadrivalent and Nonavalent
10.4. Market Value Forecast, by Indication, 2017-2031
10.4.1. Cervical Cancer
10.4.2. Anal Cancer
10.4.3. Vaginal Cancer
10.4.4. Penile Cancer
10.4.5. Vulvar Cancer
10.4.6. Oropharyngeal Cancer
10.4.7. Genital Warts
10.4.8. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
10.5.1. Physicians
10.5.2. Wholesalers
10.5.3. Physician Distributors
10.5.4. Government Entities
10.5.5. Public and Private Alliances
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Valence
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Valence, 2017-2031
11.3.1. Bivalent
11.3.2. Quadrivalent and Nonavalent
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Cervical Cancer
11.4.2. Anal Cancer
11.4.3. Vaginal Cancer
11.4.4. Penile Cancer
11.4.5. Vulvar Cancer
11.4.6. Oropharyngeal Cancer
11.4.7. Genital Warts
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Physicians
11.5.2. Wholesalers
11.5.3. Physician Distributors
11.5.4. Government Entities
11.5.5. Public and Private Alliances
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Valence
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Valence, 2017-2031
12.3.1. Bivalent
12.3.2. Quadrivalent and Nonavalent
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Cervical Cancer
12.4.2. Anal Cancer
12.4.3. Vaginal Cancer
12.4.4. Penile Cancer
12.4.5. Vulvar Cancer
12.4.6. Oropharyngeal Cancer
12.4.7. Genital Warts
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Physicians
12.5.2. Wholesalers
12.5.3. Physician Distributors
12.5.4. Government Entities
12.5.5. Public and Private Alliances
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Valence
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Valence, 2017-2031
13.3.1. Bivalent
13.3.2. Quadrivalent and Nonavalent
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Cervical Cancer
13.4.2. Anal Cancer
13.4.3. Vaginal Cancer
13.4.4. Penile Cancer
13.4.5. Vulvar Cancer
13.4.6. Oropharyngeal Cancer
13.4.7. Genital Warts
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Physicians
13.5.2. Wholesalers
13.5.3. Physician Distributors
13.5.4. Government Entities
13.5.5. Public and Private Alliances
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Valence
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Valence, 2017-2031
14.3.1. Bivalent
14.3.2. Quadrivalent and Nonavalent
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Cervical Cancer
14.4.2. Anal Cancer
14.4.3. Vaginal Cancer
14.4.4. Penile Cancer
14.4.5. Vulvar Cancer
14.4.6. Oropharyngeal Cancer
14.4.7. Genital Warts
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Physicians
14.5.2. Wholesalers
14.5.3. Physician Distributors
14.5.4. Government Entities
14.5.5. Public and Private Alliances
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Valence
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck & Co., Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AstraZeneca
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Serum Institute of India Pvt. Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Xiame Innovax Biotech Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. General Incorporated Foundation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
